market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. Securities and Exchange Commission is most often covered alongside Eli Lilly and Company, which appears in 1 of these 3 stories.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Securities and Exchange Commission
market-trends accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Source depth averages 2 original sources per story, versus 3 across the same-window beat baseline. Securities and Exchange Commission is most often covered alongside Eli Lilly and Company, which appears in 1 of these 3 stories. That works out to roughly 1.8 stories per week across a 12-day span. Their average consequence score of 5.7 runs below the beat's 5.9 for that window. Securities and Exchange Commission appears in 3 tracked Healthcare stories published from February 28, 2026 through March 11, 2026.
Stories tracked
3
Per week
1.8
Sources per story
2
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 179 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Securities and Exchange Commission. Shared-story counts are live from our verified record — not editorial picks.
Stryker, a leading global medical technology firm, has confirmed a significant cyberattack that has compromised its international network infrastructure. The incident marks another high-profile breach in the healthcare sector, raising concerns over supply chain stability for critical surgical and orthopedic equipment.
Fisher Asset Management LLC increased its position in Eli Lilly and Company by 3.5% during the third quarter, acquiring an additional 150,595 shares. The move brings the firm's total holdings to over 4.45 million shares, signaling continued institutional confidence in the pharmaceutical giant's growth trajectory.
Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3% in the third quarter, while maintaining a significant $15.45 million stake. The move reflects a strategic rebalancing as EyePoint advances its late-stage ophthalmic pipeline, particularly its DURAVYU™ platform.
Securities and Exchange Commission is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.